Abstract

In 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and preclinical researchers on specific areas of research. One of those areas involves genetic heart diseases, which are frequently caused by pathogenic variants in genes that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was initiated, focusing their research on secondary disease hits involved in the onset and progression of cardiomyopathies. Here we highlight several recent observations from our consortium and collaborators which may ultimately be relevant for clinical practice.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalNetherlands Heart Journal
Volume28
Issue numberSuppl 1
DOIs
Publication statusPublished - 1 Aug 2020

Keywords

  • Cardiomyopathies
  • Gene variants
  • Patient cohorts

Fingerprint

Dive into the research topics of 'Strength of patient cohorts and biobanks for cardiomyopathy research'. Together they form a unique fingerprint.

Cite this